J&J Building Case For Co-Administration Of Olysio With Gilead’s Sovaldi
This article was originally published in The Pink Sheet Daily
Executive Summary
Launched in the U.S. in 2013, Olysio brought in $354 million in worldwide sales during the first quarter, including $291 million in the U.S. Now, J&J will undertake a pair of Phase III trials that could back an sNDA to add co-administration with Sovaldi to the drug’s labeling.